Marc Beer set to revolutionize women’s healthcare through his MedTech startup

Marc Beer is the co-founder and CEO of Renovia; a biotechnology company focused on addressing medical problems facing women. Marc has been in the healthcare sector as an executive for over 25 years. March has dedicated most of his career towards the development of biotechnology and it’s commercialization. Renovia was founded by Marc and his business partners Yolanda Lorie and Ramon Iglesias who is currently the Managing Director in August 2016. Under the capable leadership of Marc, Renovia has grown to one of the most notable MedTech companies and successfully completed its Series A financing attracting notable healthcare venture capital funds. Before this venture, Marc worked as the Founding CEO of ViaCell and Founding Chairman of Good Star Genetics board of directors.

 

The women’s healthcare revolution

 

Recently, Marc Beer conducted a Series B financing campaign for his Renovia biotech company and successfully raised $32 million. He was also able to raise another $10 million as part of venture debt totalling his collection at $42 million. Marc plans to utilize these funds to help his company develop new products to address various medical issues related to pelvic floor disorders in women. This medical condition is known to affect at least 250 million women worldwide. Renovia, which is based in Boston is committed to developing diagnostic and therapeutic products that that can remedy pelvic floor disorders especially urinary incontinence.

 

A united front

 

During a press release announcing the collection of the funds, Marc Beer announced that his companies fight against this dreaded condition. He said that some of the company’s Series B investors had shown interest in uniting with them to help women globally manage pelvic floor disorders. Marc particularly pointed out the Longwood Fund as their partners in this united front against this condition.

 

The Renovia co-founder and CEO went ahead to state that this new investor will be very vital in the development of the second edition of their first product, Leva. The FDA approved the first edition of the Leva product in April, and Marc wants to make significant improvements to it on its second edition. The Longwood Fund’s long-term experience as a healthcare-focused investment firm will play a significant role in this according to Beer.

 

Cheaper healthcare

 

Beer went ahead to state that by Renovia working closely with the Longwood Fund, it will be possible for them to lower the cost of this healthcare for women across the globe. He stated that by the two companies combining their proprietary innovative sensor technologies, they could come up with affordable treatment options. Marc Beer said that his company planned to use its digital health platform to provide its customers with valuable data that will help them make informed decisions. Learn more: https://www.cnbc.com/video/2013/01/23/aegerion-ceo-on-promise-of-biopharma.html

 

Leave a Reply

Your email address will not be published. Required fields are marked *